Sonoma Pharmaceuticals (SNOA) Capital Leases (2017 - 2018)
Sonoma Pharmaceuticals' (SNOA) quarterly Capital Leases came in at $62000.0 in Q3 2018, down 71.69% year-on-year from $219000.0 in Q3 2017, and down 40.38% quarter-over-quarter from $104000.0 in Q2 2018.
Sonoma Pharmaceuticals (SNOA) Capital Leases (2017 - 2018) Analysis & Trends
Sonoma Pharmaceuticals' Capital Leases history runs 2 years deep, the most recent figure standing at $62000.0 for Q3 2018.
- On a quarterly basis, Capital Leases fell 71.69% year-over-year to $62000.0 in Q3 2018; TTM through Sep 2018 was $62000.0, a 71.69% decrease from a year earlier, with the FY2018 full-year figure at $144000.0, down 14.29% from the prior year.
- Capital Leases slipped to $62000.0 in Q3 2018 per SNOA's latest filing, from $104000.0 in the prior quarter.
- Across five years, Capital Leases topped out at $252000.0 in Q2 2017 and bottomed at $62000.0 in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Sonoma Pharmaceuticals | 179.80 | -2.40 Mn | 2.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 62,000.00 |
| Jun 30, 2018 | 104,000.00 |
| Mar 31, 2018 | 144,000.00 |
| Dec 31, 2017 | 179,000.00 |
| Sep 30, 2017 | 219,000.00 |
| Jun 30, 2017 | 252,000.00 |
| Mar 31, 2017 | 168,000.00 |